News
Public · Published
Ascletis to Present Study Results of Oral Small Molecule GIPR Agonist ASC48 and GLP-1R/GIPR/GCGR Triple Peptide Agonist ASC37 at ObesityWeek® 2026
Ascletis announced two poster presentations on its obesity drug candidates, oral small molecule GIPR agonist ASC48 and triple peptide agonist ASC37, at ObesityWeek 2026, scheduled for November 14–17 in Washington, DC. The posters will present preclinical laboratory and animal-study data.
Published:
Updated:
What happened
Ascletis announced two poster presentations on its obesity drug candidates, oral small molecule GIPR agonist ASC48 and triple peptide agonist ASC37, at ObesityWeek 2026, scheduled for November 14–17 in Washington, DC. The posters will present preclinical laboratory and animal-study data.
Confirmed
Global impact / market context
The presentations may help investors assess how early Ascletis’s obesity programs are progressing, but the reported evidence is preclinical, meaning it comes from laboratory and animal studies rather than patient trials. Any path to revenue depends on further development and evidence of safety and effectiveness in people.
Analyst inference
ASC48 and ASC37 are two different approaches: ASC48 is an oral small molecule, while ASC37 is a peptide described as potentially dosed once monthly to once quarterly. The article reports planned presentations, not clinical results, regulatory approval, sales, or a change to development plans.
Confirmed
What to watch
- At the November 14 poster session, check what data Ascletis presents for ASC48 and whether the preclinical findings provide detail beyond the announced in vitro and in vivo studies. Analyst inference
- Review the ASC37 poster’s reported half-life comparison and weight-loss findings, while noting that the title specifies nonhuman primates and diet-induced-obesity mice, not human participants. Confirmed
- Watch for any later company updates on clinical testing, since evidence in people would be needed to judge whether these candidates can progress toward treatment use and potential revenue. Analyst inference
Evidence
- Original source link unavailable